Member Note: The PSA understands that there is another event, at the same venue, on July 18th. It is our expectations that all PSA members will attend our event than any other organization. Our event is being sponsored by Dan Killian’s Harvard Investors and Dan is a member and loyal supporter of the PSA. Please register and support the PSA on July 18th.
The Capital Grille
1338-46 Chestnut Street
Philadelphia, PA 19107
Date: Tuesday, July 18th, 12:00 pm (Doors open at 11:30 am)
Ori Warshavsky, Chief Operating Officer
Ori Warshavsky has over 15 years of international experience in the pharmaceuticals industry with experience ranging from corporate strategy and business development to marketing and market access. Prior to joining Polypid Ori spent 10 years at Teva Pharmaceuticals with his last role being Senior Director of Oncology Marketing where he led the launch of several oncology products. Earlier in his career Ori served as the Head of Market Access for Teva in Canada, and as Chief of Staff to the CEO of Teva’s global generics business. Ori started his career as a biotech engineer both in Israel and the US.
Ori holds a B.Sc. degree in Biotechnology Engineering from the Ben-Gurion University in Israel and an MBA from Duke University’s Fuqua School of Business.
We are a global clinical-stage bio-pharmaceutical company focused on developing, manufacturing and commercializing novel, locally administered therapies to improve surgical outcomes.
Our PLEX (Polymer-Lipid Encapsulation matriX) technology is a unique platform that is anchored in the surgical site to provide controlled and continuous delivery of medications.
Our product candidates are designed to deliver medications in the body over days to several months in a controlled manner. This allows surgeons to deliver medication right to the surgical site to improve patient outcomes in localized medical conditions such as; infection, pain, inflammation and cancer.
Our initial infection treatment targets are Surgical Site Infections (SSIs), the second most prevalent type of Healthcare Acquired Infections (HAIs). SSIs have substantial negative impact on patients’ clinical outcomes and also pose a significant healthcare system burden1.
We strive to reduce overall surgical infection rates, including infections due to antibiotic-resistant bacteria which the FDA defined as being one of the world’s most pressing public health problems².
Our strategy has two elements:
- Development of our proprietary product pipeline
Collaborations with pharma companies to improve the local delivery of their medications